

## Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023

### Description

CORAL GABLES, Fla., Aug. 1, 2023 /PRNewswire/ — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 8, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Tuesday, August 8, 2023.

[Relmada Therapeutics Corporate Logo \(PRNewsFoto/Relmada Therapeutics, Inc.\)](#)

### Live Conference Call & Webcast:

Toll Free: 877-407-0792

International: 201-689-8263

Conference ID: 13740070

Webcast: [https://viaid.webcasts.com/starthere.jsp?ei=1624681&tp\\_key=1f9f03a8ac](https://viaid.webcasts.com/starthere.jsp?ei=1624681&tp_key=1f9f03a8ac)

A replay of the webcast will be available in the Investors section of the Relmada website at <https://www.relmada.com/investors/ir-calendar>.

### About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). The ongoing Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment.

### About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at [www.relmada.com](http://www.relmada.com).

## **Forward-Looking Statements**

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of Phase III trial results to demonstrate clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of a trial, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

## **Investor Contact:**

Tim McCarthy  
LifeSci Advisors  
[Tim@LifeSciAdvisors.com](mailto:Tim@LifeSciAdvisors.com)

## **Media Inquiries:**

Corporate Communications  
[media@relmada.com](mailto:media@relmada.com)

📄 View original content to download multimedia: <https://www.prnewswire.com/news-releases/relmada-therapeutics-to-report-second-quarter-2023-financial-results-and-host-conference-call-and-webcast-on-august-8-2023-301890155.html>

SOURCE Relmada Therapeutics, Inc.

Released August 1, 2023

**Date Created**

2023/08/01